Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...

I was diagnosed with relapsing-remitting multiple sclerosis (RRMS) at the age of 46.

The US FDA has approved ocrelizumab (Ocrevus, Genentech) intravenous infusion for children aged 10 years and older with relapsing-remitting multiple sclerosis (RRMS) who weigh at least 55 lbs (25 kg), ...

AHSCT resets the immune system in highly active RRMS after high-efficacy drugs fail, delivering higher NEDA, fewer relapses, and durable function gains. When high-efficacy drugs stop holding relapsing ...

Natalizumab is a high-efficacy monoclonal antibody employed in the treatment of relapsing forms of multiple sclerosis. Its mechanism, which involves blockade of α4-integrin on lymphocytes, strongly ...

Progressive multiple sclerosis encompasses both primary and secondary forms characterised by a sustained increase in neurological disability independent of acute relapses. Pathologically, it reflects ...

A major international phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab – a medication already prescribed to some patients with MS – significantly slows ...

A major international Phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab—a medication already prescribed to some patients with MS—significantly slows ...

Paris, December 24, 2025. The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the new drug application of tolebrutinib to treat non-relapsing secondary ...